Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (71-80 of 211) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple MyelomaKeiji Kurata, Mehmet K Samur, Priscilla Liow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2023
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple MyelomaKeiji Kurata, Mehmet K Samur, Priscilla Liow, et al.
Leukemia|February 16, 2020
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myelomaLijie Xing, Liang Lin, Tengteng Yu, et al.
Blood|May 22, 2016
A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacyJianhong Lin, Weihong Zhang, Jian-Jun Zhao, et al.
Blood|November 16, 2002
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signalingYu-Tzu Tai, Klaus Podar, Nicholas Mitsiades, et al.
Leukemia|January 27, 2022
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Experimental Hematology|July 24, 2002
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cellsDeepak Gupta, Klaus Podar, Yu Tzu Tai, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaKlaus Podar, Giovanni Tonon, Martin Sattler, et al.
Leukemia|May 5, 2022
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
British Journal of Haematology|September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implicationsKlaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Pageof 22

Showing results (71-80 of 211) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple MyelomaKeiji Kurata, Mehmet K Samur, Priscilla Liow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2023
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple MyelomaKeiji Kurata, Mehmet K Samur, Priscilla Liow, et al.
Leukemia|February 16, 2020
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myelomaLijie Xing, Liang Lin, Tengteng Yu, et al.
Blood|May 22, 2016
A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacyJianhong Lin, Weihong Zhang, Jian-Jun Zhao, et al.
Blood|November 16, 2002
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signalingYu-Tzu Tai, Klaus Podar, Nicholas Mitsiades, et al.
Leukemia|January 27, 2022
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
Experimental Hematology|July 24, 2002
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cellsDeepak Gupta, Klaus Podar, Yu Tzu Tai, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2006
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaKlaus Podar, Giovanni Tonon, Martin Sattler, et al.
Leukemia|May 5, 2022
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSophia Adamia, Shruti Bhatt, Kenneth Wen, et al.
British Journal of Haematology|September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implicationsKlaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Pageof 22